Shenzhen Chipscreen Biosciences Co., Ltd. (SHA:688321)
China · Delayed Price · Currency is CNY 31.15
+0.58 (1.90%)
Feb 3, 2026, 3:00 PM CST
SHA:688321 Revenue
Shenzhen Chipscreen Biosciences had revenue of 267.56M CNY in the quarter ending September 30, 2025, with 49.51% growth. This brings the company's revenue in the last twelve months to 850.99M, up 29.68% year-over-year. In the year 2024, Shenzhen Chipscreen Biosciences had annual revenue of 657.95M with 25.63% growth.
Revenue (ttm)
850.99M
Revenue Growth
+29.68%
P/S Ratio
14.93
Revenue / Employee
802.82K
Employees
973
Market Cap
12.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 657.95M | 134.24M | 25.63% |
| Dec 31, 2023 | 523.71M | -6.23M | -1.18% |
| Dec 31, 2022 | 529.94M | 99.49M | 23.11% |
| Dec 31, 2021 | 430.45M | 160.98M | 59.74% |
| Dec 31, 2020 | 269.47M | 95.67M | 55.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Hisun Pharmaceutical | 9.84B |
| Shanghai Shyndec Pharmaceutical | 9.36B |
| Zhejiang Medicine | 8.96B |
| Zhejiang Jingxin Pharmaceutical | 4.00B |
| Henan Lingrui Pharmaceutical | 3.78B |
| Mayinglong Pharmaceutical Group | 3.77B |
| Porton Pharma Solutions | 3.43B |
| Beijing Foyou Pharma CO.,LTD | 3.42B |